Business
Goldman Sachs Retains Buy on Cohance Lifesciences, Cuts Estimates
Goldman Sachs has retained its Buy rating on Cohance Lifesciences with a target price of 525 rupees. However, the brokerage slashed its fiscal 2027 to 2029 earnings estimates by up to 31 percent. This move highlights a cautious outlook among market analysts despite their continued confidence in the company's stock performance.
Read news like this in 60 seconds
Short2News gives you the day's news as fast 60-word cards, in your own language.
- News in Telugu, Hindi, Tamil, Kannada and eight more languages
- Short summaries with the source on every story
- Read aloud, so you can listen hands-free
- Post from your area and earn rewards
More Top Stories
రూ.35లకే సినిమాలతో వీఐ కొత్త రీఛార్జ్ ప్లాన్!
US Criticized for Not Warning Nvidia CEO Over Alleged Ties
Bank Holidays Today: Check State-Wise Diwali Closures
Japan's Current Account Surplus Drops Sharply in September 2026
NSE And BSE Closed On November 10 For Trading
Are Banks Open Or Closed Today On November 10?